GH Research GHRS
NASDAQ GHRS
$28.04 +0.12 (+0.43%)
As of: Sep 4, 2026 · 1:20 PM EDT

GH Research (GHRS) Non Operating Interest Expenses (2021 - 2026)

Analysis

GH Research (GHRS) Non Operating Interest Expenses (2021 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 139.27 Bn 131.42 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.55 Bn 77.56 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.45 Bn 58.27 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.73 Bn 52.59 Bn 52.00 Mn -
5 Revolution Medicines 44.08 Bn 44.08 Bn - 23.78 Mn
6 BeOne Medicines 39.95 Bn 34.85 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.14 Bn 31.84 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.44 Bn 27.60 Bn - 93.62 Mn
9 Insmed 27.32 Bn 26.16 Bn 358.27 Mn 20.27 Mn
10 GH Research 1.71 Bn 1.35 Bn - -83,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -83,000.00
Mar 31, 2026 -84,000.00
Dec 31, 2025 -90,000.00
Sep 30, 2025 -21,000.00
Jun 30, 2025 -174,000.00
Mar 31, 2025 -178,000.00
Dec 31, 2024 -179,000.00
Sep 30, 2024 -181,000.00
Jun 30, 2024 -178,000.00
Mar 31, 2024 -179,000.00
Dec 31, 2023 -189,000.00
Sep 30, 2023 -184,000.00
Jun 30, 2023 -179,000.00
Mar 31, 2023 -171,000.00
Dec 31, 2022 123,000.00
Sep 30, 2021 -3,000.00
Jun 30, 2021 -6,000.00